{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:51:44Z","timestamp":1772779904157,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.ejim.2009.05.004","type":"journal-article","created":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T08:26:57Z","timestamp":1246436817000},"page":"562-568","source":"Crossref","is-referenced-by-count":31,"title":["A new era for anticoagulants"],"prefix":"10.1016","volume":"20","author":[{"given":"Massimo","family":"Franchini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Mannuccio","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2009.05.004_bib1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1055\/s-2008-1047567","article-title":"The future of anticoagulation","volume":"29","author":"Hoppensteadt","year":"2008","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MOH.0b013e328309ecbc","article-title":"New anticoagulants","volume":"15","author":"Bauer","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.ejim.2009.05.004_bib3","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/sj.bjp.0706153","article-title":"New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin","volume":"14","author":"Bates","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejim.2009.05.004_bib4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCULATIONAHA.106.685974","article-title":"Beyond unfractionated heparin and warfarin: current and future advances","volume":"116","author":"Hirsh","year":"2007","journal-title":"Circulation"},{"issue":"3 Suppl","key":"10.1016\/j.ejim.2009.05.004_bib6","first-page":"133S","article-title":"Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2009.05.004_bib7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2003-12-4195","article-title":"New anticoagulants","volume":"105","author":"Hirsh","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2009.05.004_bib9","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1538-7836.2005.01374.x","article-title":"New anticoagulants","volume":"3","author":"Weitz","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2009.05.004_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1055\/s-2008-1066025","article-title":"Survival of heparins, oral anticoagulants, and aspirin after the year 2010","volume":"34","author":"Fareed","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ejim.2009.05.004_bib11","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1055\/s-0029-1145260","article-title":"Development of new anticoagulants: present and future","volume":"34","author":"Harenberg","year":"2008","journal-title":"Semin Thromb Haemost"},{"key":"10.1016\/j.ejim.2009.05.004_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-2008-1066023","article-title":"Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa","volume":"34","author":"Harenberg","year":"2008","journal-title":"Semin Thromb Haemost"},{"key":"10.1016\/j.ejim.2009.05.004_bib13","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/med.20100","article-title":"Recent advances in the treatment of thromboembolic diseases: venous thromboembolism","volume":"27","author":"Agrawal","year":"2007","journal-title":"Med Res Rev"},{"key":"10.1016\/j.ejim.2009.05.004_bib14","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"Bijsterveld","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2009.05.004_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1055\/s-2002-34309","article-title":"The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa","volume":"28","author":"Petitou","year":"2002","journal-title":"Semin Thromb Haemost"},{"key":"10.1016\/j.ejim.2009.05.004_bib16","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of VTE after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib17","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of VTE in elective hip-replacement surgery: a randomised double-blind comparison","volume":"359","author":"Lassen","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2009.05.004_bib18","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of VTE after elective hip replacement surgery: a randomised double-blind trial","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2009.05.004_bib19","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of VTE after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib20","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib21","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.163.11.1337","article-title":"PENTasaccharide in HIp-FRActure Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study","volume":"163","author":"Eriksson","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib22","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/bjs.5154","article-title":"PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery","volume":"92","author":"Agnelli","year":"2005","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejim.2009.05.004_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","article-title":"Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial","volume":"332","author":"Cohen","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2009.05.004_bib24","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"Buller","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib25","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib26","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib27","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2009.05.004_bib28","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.108.789479","volume":"118","author":"Mehta","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2009.05.004_bib29","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"Buller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib30","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa067703","article-title":"van Gogh Investigators. Extended prophylaxis of venous thromboembolism with idraparinux","volume":"357","author":"Buller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(08)60168-3","article-title":"Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, noninferiority trial","volume":"371","author":"Bousser","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2009.05.004_bib32","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1538-7836.2008.02943.x","article-title":"Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials","volume":"6","author":"Harenberg","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2009.05.004_bib33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1742-1241.2009.02011.x","article-title":"New oral anticoagulants","volume":"63","author":"Khoo","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ejim.2009.05.004_bib34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2147\/VHRM.S3550","article-title":"New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban","volume":"4","author":"Borris","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.ejim.2009.05.004_bib35","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"RECORD1 Study Group. Rivaroxaban versusenoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2009.05.004_bib37","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib38","series-title":"Proceedings of the 9th EFORT Congress, Nice, May 30, 2008","article-title":"Comparison of rivaroxaban, an oral direct factor Xa inhibitor, and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD 4: a phase III study)","author":"Turpie","year":"2008"},{"key":"10.1016\/j.ejim.2009.05.004_bib39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2009.05.004_bib40","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2009.05.004_bib41","doi-asserted-by":"crossref","unstructured":"Haas S. Rivaroxaban \u2014 an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme. Eur J Haematol 2009;82:339\u201349.","DOI":"10.1111\/j.1600-0609.2009.01230.x"},{"key":"10.1016\/j.ejim.2009.05.004_bib42","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2009.05.004_bib43","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","article-title":"Botticelli Investigators, Writing Committee. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study","volume":"6","author":"Buller","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2009.05.004_bib44","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.thromres.2008.08.003","article-title":"The top 4 advances in antithrombotic care in the last year","volume":"123","author":"Turpie","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2009.05.004_bib45","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/asheducation-2006.1.450","article-title":"New anticoagulants","author":"Bauer","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ejim.2009.05.004_bib46","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2009.05.004_bib47","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2009.05.004_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Ginsberg","year":"2009","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.ejim.2009.05.004_bib49","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","article-title":"Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)","volume":"100","author":"Ezekowitz","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2009.05.004_bib50","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1046\/j.1538-7836.2003.00368.x","article-title":"Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study","volume":"1","author":"Colwell","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2009.05.004_bib51","doi-asserted-by":"crossref","first-page":"648","DOI":"10.7326\/0003-4819-137-8-200210150-00008","article-title":"Ximelagatran versus warfarin for the prevention of VTE after total knee arthroplasty","volume":"137","author":"Francis","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib52","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1056\/NEJMoa035162","article-title":"EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement","volume":"349","author":"Francis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib53","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2106\/JBJS.D.02184","article-title":"EXULT B Study Group. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty","volume":"87","author":"Colwell","year":"2005","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ejim.2009.05.004_bib54","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1055\/s-0037-1613445","article-title":"METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of VTE after total hip or knee joint replacement","volume":"89","author":"Eriksson","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2009.05.004_bib55","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1111\/j.1538-7836.2003.00494.x","article-title":"EXPRESS Study Group. The oral direct thrombin inhibitor ximelagatran, and its subcutaneous form melagatran, compared with enoxaparin for prophylaxis of VTE in total hip or total knee replacement: the EXPRESS study","volume":"1","author":"Eriksson","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2009.05.004_bib56","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2009.05.004_bib57","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","article-title":"THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial","volume":"293","author":"Fiessinger","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2009.05.004_bib58","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2009.05.004_bib59","first-page":"690","article-title":"SPORTIF Executive Steering Committee for the SPORTIF V Investigators","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA"},{"issue":"14 Suppl","key":"10.1016\/j.ejim.2009.05.004_bib60","first-page":"S462","article-title":"SPORTIF Investigators. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials","volume":"10","author":"Albers","year":"2004","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ejim.2009.05.004_bib61","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620509000892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620509000892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T04:55:45Z","timestamp":1558414545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620509000892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0953620509000892"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2009.05.004","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}